Bremelanotide (Vyleesi / PT-141): What Women Need to Know Before Asking for a Prescription

What Bremelanotide Is and How It Got Approved

Bremelanotide is a synthetic cyclic heptapeptide analog of alpha-melanocyte stimulating hormone. It activates melanocortin receptors (MC3R and MC4R) in the central nervous system, shifting sexual motivation pathways that are distinct from any hormonal target. The FDA granted approval on June 21, 2019, making bremelanotide the second drug cleared specifically for HSDD after flibanserin (Addyi) in 2015 [1].

The approval was based on two phase 3 randomized, placebo-controlled trials known collectively as RECONNECT (Studies 301 and 302). Together they enrolled 1,247 premenopausal women with acquired, generalized HSDD confirmed by the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) [2]. Women with anatomical causes of sexual dysfunction, active depression requiring treatment, or relationship distress as the primary driver were excluded.

The FDA label specifies two co-primary endpoints: the change in the number of satisfying sexual events (SSEs) per month and the change in the sexual desire domain score on the FSDS-DAO [1]. Both endpoints reached statistical significance, though the absolute gains were modest. The label carries a frank statement that the mean increase in SSEs was approximately 0.5 events per month compared with placebo. Clinicians at the FDA noted during the advisory committee review that "the magnitude of benefit is small," but the committee voted to approve because the unmet need in HSDD is large and the drug's non-hormonal mechanism offers a distinct option [1].

How PT-141 Differs from Flibanserin (Addyi)

Flibanserin (Addyi) and bremelanotide both target HSDD, but they work through entirely separate mechanisms and have different administration requirements.

Flibanserin is a serotonin 1A receptor agonist and 2A receptor antagonist taken as a 100 mg oral tablet every night at bedtime [3]. Its effect builds over weeks of daily use. In the DAISY trial (N=1,378), flibanserin increased SSEs by 0.5 to 1.0 events per month over placebo at 24 weeks [4]. Because flibanserin interacts with the cytochrome P450 3A4 enzyme, it carries a Risk Evaluation and Mitigation Strategy (REMS) requiring patients to avoid alcohol and strong CYP3A4 inhibitors, including fluconazole [3].

Bremelanotide, by contrast, is used as needed rather than daily. A woman injects 1.75 mg subcutaneously into the abdomen or thigh 45 minutes before she anticipates sexual activity, up to once every 24 hours [1]. There is no alcohol restriction, though transient nausea affects roughly 40% of users in trials, and transient increases in blood pressure averaging 6 mmHg systolic can occur in the first 12 hours after dosing [2]. For this reason, bremelanotide is contraindicated in women with known cardiovascular disease or uncontrolled hypertension [1].

The practical choice between the two drugs often comes down to lifestyle fit. Daily pill takers who prefer to "set and forget" a regimen may find flibanserin easier. Women who want a situational option and can tolerate a brief injection may prefer bremelanotide. Both require a prescription, and neither is appropriate for postmenopausal HSDD, where the evidence base is weaker.

Dosing, Administration, and What to Expect the First Time

The approved dose is fixed at 1.75 mg. No titration schedule exists. The auto-injector is a single-use prefilled device similar in size to an allergy pen [1].

Inject into the abdomen or thigh 45 minutes before anticipated activity. Peak plasma concentration occurs at approximately 1 hour. The half-life is roughly 2.7 hours, but the pharmacodynamic window for sexual response may extend to 12 hours in some women [2]. Use no more than one dose in any 24-hour period. The FDA label does not specify a monthly maximum dose, but clinical study protocols capped use at approximately 8 doses per month, and long-term safety data beyond that frequency are limited [1].

On the first injection, sit or lie down for at least 30 minutes afterward. Nausea, if it occurs, typically begins within 30 to 60 minutes and resolves within 2 hours. Taking the injection on an empty stomach worsens nausea; a light meal or snack before dosing reduces it [2]. Flushing and mild injection-site bruising are also common. Blood pressure elevation is transient and self-limiting in healthy women, but home blood pressure monitoring on the first use is reasonable if any cardiac risk factors are present.

Who Should Not Use Bremelanotide

Contraindications are not minor. The FDA label lists known cardiovascular disease and uncontrolled hypertension as absolute contraindications because of the transient pressor effect [1]. Concomitant use of naltrexone or naloxone is also contraindicated because these opioid antagonists block MC4R downstream signaling and may diminish bremelanotide's effect while increasing cardiovascular risk [1].

Women with a history of focal migraine with aura should discuss risk with their prescriber before use, as the blood pressure increase, though small, may be relevant in this population. Pregnancy is another contraindication; bremelanotide is approved only for premenopausal women, and animal reproductive toxicity data exist [1].

HSDD must be properly diagnosed before prescribing. The diagnosis requires distress about low desire and rules out relationship factors, untreated depression, and medication side effects (selective serotonin reuptake inhibitors are a common driver of HSDD). A structured tool such as the FSFI or DESIRE questionnaire should be part of any workup [5].

Bremelanotide vs. Vaginal Estradiol: Two Different Problems

Vaginal estradiol does not treat HSDD. Bremelanotide does not treat vaginal dryness.

This distinction matters clinically because many women present with both complaints, and prescribers sometimes conflate them. Genitourinary syndrome of menopause (GSM), formerly called vulvovaginal atrophy, involves thinning of vaginal epithelium, reduced lubrication, and dyspareunia, all driven by estrogen depletion [6]. Vaginal estradiol (available as Estrace 0.01% cream, Vagifem tablets 10 mcg, or the Estring ring) delivers estrogen locally with minimal systemic absorption. The Cochrane review of vaginal estrogen for GSM (27 trials, N=6,235) found statistically significant improvements in vaginal dryness, pH, and dyspareunia versus placebo, with systemic estradiol levels remaining below postmenopausal range in most preparations [7].

Bremelanotide, acting centrally, does not change vaginal tissue integrity. A woman with pure GSM and no desire disorder needs vaginal estradiol, not bremelanotide. A woman with both conditions may need both, though that combination has not been formally studied in a randomized trial.

Vaginal DHEA (Prasterone / Intrarosa): The Middle-Ground Option

Prasterone (brand name Intrarosa), the intravaginal insert form of dehydroepiandrosterone (DHEA), received FDA approval in November 2016 for dyspareunia due to menopause [8]. It works differently from estradiol: intravaginal DHEA is locally converted to both estrogen and testosterone within vaginal cells through intracrinology, raising local sex steroid concentrations with minimal change in serum estradiol [9].

The AMETHYST trial (N=464) showed that prasterone 6.5 mg daily significantly improved the severity of the most bothersome symptom of dyspareunia versus placebo at 12 weeks (P<0.001) and improved the vaginal maturation index, a measure of epithelial health [9]. Unlike systemic DHEA, intravaginal prasterone does not appear to raise serum estradiol meaningfully above postmenopausal baseline, making it an option for women with estrogen-sensitive cancer histories who need genitourinary relief, though oncology consultation is still warranted in that scenario.

Prasterone addresses tissue-level dryness and pain, not central desire. For women whose main complaint is low libido without significant GSM, bremelanotide or flibanserin is the more logical starting point.

Compounded Testosterone Cream for Women: Off-Label but Guideline-Supported

No FDA-approved testosterone product exists for women in the United States. Yet the Endocrine Society's 2019 clinical practice guideline on testosterone therapy states that testosterone may be considered for postmenopausal women with HSDD after other causes have been excluded, at doses producing blood levels in the normal premenopausal female range (total testosterone roughly 15 to 70 ng/dL) [10].

Compounded testosterone cream (typically 0.5 to 2 mg per gram, applied topically to the inner thigh or forearm daily) is the most commonly prescribed form in the US because no commercial product delivers the low doses women need. A 2019 meta-analysis published in The Lancet Diabetes and Endocrinology (36 trials, N=8,480 women) found that testosterone significantly improved sexual function scores, specifically desire, arousal, orgasm, and pleasure, versus placebo or comparator, with the greatest benefit in postmenopausal women [11].

Monitoring requires serum total testosterone at baseline and 4 to 6 weeks after initiation, then every 6 months. Androgenic side effects (acne, unwanted hair growth) are dose-dependent and generally mild at physiologic doses, reversing on dose reduction [10]. Compounded preparations are not FDA-regulated for quality the way branded drugs are, so pharmacy selection and formulation consistency matter. The Endocrine Society guideline advises against supraphysiologic dosing and states providers should "use the lowest dose consistent with therapeutic benefit" [10].

The practical decision framework a HealthRX clinician applies to a woman presenting with low sexual desire looks like this. First, clarify the primary complaint: is it low desire, painful sex, dryness, difficulty with arousal, or orgasmic difficulty? Each maps to a different treatment pathway. Low desire without GSM in a premenopausal woman points to HSDD screening and bremelanotide or flibanserin evaluation. Low desire with GSM in a postmenopausal woman points to vaginal estradiol or prasterone first, then testosterone assessment if desire remains low after GSM is treated. A postmenopausal woman with clear HSDD and no GSM is a candidate for compounded testosterone. Bremelanotide in postmenopausal women remains off-label and lacks phase 3 data in that population.

Safety Data Beyond the Key Trials

The RECONNECT open-label extension followed 684 women for up to 52 weeks of as-needed bremelanotide use [2]. No new safety signals emerged. The most common reason for discontinuation in the extension was nausea (6.3%) and flushing (2.8%). No cases of serious cardiovascular events were attributed to bremelanotide in the study population, though the trials excluded women with cardiovascular risk factors, limiting generalizability [2].

A pharmacovigilance concern that emerged post-approval involves focal hyperpigmentation. The FDA label notes that prolonged or frequent use may cause focal hyperpigmentation of the face, breast, or gums in some patients [1]. This effect is mechanistically expected, since MC1R (melanocyte-stimulating receptor) shares the melanocortin family with the MC3R and MC4R targets. Pigmentation changes may not fully reverse on drug discontinuation, and women with darker skin tones warrant specific counseling on this risk [1].

Renal and hepatic impairment also affect bremelanotide exposure. Severe renal impairment (creatinine clearance <30 mL/min) increases the area under the plasma concentration-time curve by 60%, and severe hepatic impairment nearly doubles it; use is not recommended in either group [1].

Talking to a Prescriber: What to Bring to the Appointment

A structured approach saves time. Before the appointment, track the number of sexual events (satisfying and unsatisfying) over four weeks in a simple calendar. Complete the Female Sexual Function Index (FSFI) online; a score below 26.55 is the validated threshold associated with female sexual dysfunction [5]. Note all current medications, especially antidepressants, antihypertensives, and any opioid-based pain medications, as these interact or contraindicate both HSDD treatments.

Bring up any prior breast, uterine, or ovarian cancer history, since it affects estrogen and testosterone options even when bremelanotide itself is technically permissible. Clarify whether desire is the primary problem or whether pain and dryness are secondary contributors, because that single distinction drives the entire prescription decision.

The North American Menopause Society (NAMS) 2022 position statement on hormone therapy notes that "sexual health is an important component of overall wellbeing and should be routinely assessed in clinical practice," yet surveys consistently show fewer than 30% of primary care visits include a sexual health question [12]. Raising the topic directly shortens time to appropriate treatment.

Cost, Insurance Coverage, and Telehealth Access

Bremelanotide carries a list price near $800 to $1,000 for a four-dose pack of auto-injectors. Commercial insurance coverage is inconsistent; many plans classify it as a lifestyle drug and deny coverage without a prior authorization documenting HSDD diagnosis, failed behavioral therapy, and ruling out relationship or psychiatric causes [1]. Palatin Technologies, the manufacturer, offers a patient savings program that may reduce out-of-pocket cost to roughly $99 per month for eligible commercially insured patients.

Flibanserin is somewhat less expensive, with generic versions available since 2021 at roughly $200 to $400 per month wholesale, though compounded versions through 503A pharmacies may be lower. Compounded testosterone cream can cost $30 to $100 per month depending on dose and pharmacy. Vaginal estradiol (Estrace generic) and prasterone (Intrarosa) run $30 to $150 per month depending on formulation and pharmacy benefit.

Telehealth prescribing of bremelanotide is legal in most US states, but requires a full intake including medical and sexual history and ideally a validated instrument like the FSFI. HealthRX clinicians complete this evaluation asynchronously with follow-up available for questions after the first injection.